UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
NOVEMBER 14 2005
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
DIRECTOR/PDMR SHAREHOLDING
TRADING IN NOVO NORDISK SHARES BY BOARD MEMBERS, EXECUTIVES AND ASSOCIATED
PERSONS AS REPORTED TO NOVO NORDISK ON 10 NOVEMBER 2005
In accordance with Section 28a of the Danish Securities Trading Act, Novo
Nordisk is required on a daily basis to publish trading in Novo Nordisk shares
by the company's board members, executives and their associated persons as
reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Name Kurt Briner
Reason for reporting Board member
Financial instrument and ID code Novo Nordisk B shares
DK 001028081
Type of transaction Sale of shares
Date of transaction 8 November 2005
Place of transaction Copenhagen Stock Exchange
Volume of transaction 2,400 shares
Total value of transaction DKK 808,800
DEFINITIONS AND BACKGROUND INFORMATION:
PUBLICATION
Publication shall take place the day after Novo Nordisk receives sufficient
information on the trading. Publication is only required when the total amount
of transactions of a specific board member/executive and his/her associated
persons in any one calendar year has reached 5,000 euros.
WHO ARE BOARD MEMBERS, EXECUTIVES AND ASSOCIATED PERSONS?
Board members and executives are members of the Board of Directors and Executive
Management, respectively, of Novo Nordisk A/S. Associated persons are defined as
the following persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) relatives defined as
brothers, sisters, parents, grandparents etc, children, grandchildren etc who
have shared the same household with a board member/executive for at least one
year, and 4) any legal person, including a company, a foundation or a
partnership, which is controlled directly or indirectly by a board
member/executive and/or a person mentioned in 1)-3), or to which a board
member/executive and/or a person mentioned in 1)-3) has managerial
responsibilities or economic interests substantially equivalent to the legal
person.
WHAT IS TRADING/TRANSACTION?
Trading is any kind of transaction, including shares purchased or otherwise
acquired, shares sold or otherwise disposed, gifts, mortgages and grants and
exercise of options, but not heritage.
WHAT IS FINANCIAL INSTRUMENT AND ID CODE?
Financial instrument includes shares listed on the Copenhagen Stock Exchange and
London Stock Exchange as well as ADRs listed on New York Stock Exchange, except
for ADRs held in 401(k) retirement plan by US-based employees. The ID code is
the code (ISIN DK001028081) of the Novo Nordisk share on the Copenhagen Stock
Exchange, the code (NVOB) on London Stock Exchange or the code (NVO) on New York
Stock Exchange.
WHAT IS DATE AND PLACE OF TRANSACTION?
Date of transaction is the actual transaction date. The place of transaction is
the actual place of transaction, ie Copenhagen Stock Exchange, London Stock
Exchange or New York Stock Exchange.
WHAT IS VOLUME AND VALUE OF TRANSACTION?
The volume of transaction is the number of shares (of DKK 2 nominal value) or
other financial instruments traded. The transaction value is the number of
shares traded multiplied by the transaction price. The exchange rate of the
Danish Central Bank (Nationalbanken) on the date of transaction is used for
calculating the transaction value in DKK in case of shares traded on London
Stock Exchange and ADRs listed on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The
company has the broadest diabetes product portfolio in the industry, including
the most advanced products within the area of insulin delivery systems. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 21,600 full-time
employees in 78 countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.
Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For
more information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mogens Thorsager Jensen
Tel (direct): Tel (direct):
(+45) 4442 3450 (+45) 4442 7945
Christian Qvist Frandsen
Tel (direct):
(+45) 4443 5182
In North America: In North America:
Susan T Jackson Mads Veggerby Lausten
Tel (direct): Tel (direct):
(+1) 609 919 7776 (+1) 609 919 7937
Stock Exchange Announcement no 27/2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: NOVEMBER 14 2005 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer